Skip to main content

The Jackson Laboratory

Home

Recent Searches

Share this Post

Share on facebook
Share on twitter
Share on linkedin
Share on email

Home
PEGS Europe: Protein & Antibody Engineering Summit
Poster: A Humanized In Vivo System to Predict Antibody-induced Cytokine Release Syndrome

Poster: A Humanized In Vivo System to Predict Antibody-induced Cytokine Release Syndrome

Published Date October 25, 2021

Fill form to unlock content

Loading, please wait

Error - something went wrong!

Access Content

Thank you!

Previous Flipbook

A New Way to Study Cytokine Release Syndrome

In vivo CRS assays have the potential to simultaneously derisk and accelerate the process of bringing successful therapies to the patients who need them most.
Next Video

A Humanized Preclinical in Vivo System to Predict the Immunotoxicity of Antibody Drug Candidates

James Keck, Ph.D., Senior Director, Innovation and Product Development, at JAX speaks about a humanized preclinical in vivo system to predict the the immunotoxicity of antibody drug candidates.

Other content in this Stream

about 2 years ago
A New Way to Study Cytokine Release Syndrome

In vivo CRS assays have the potential to simultaneously derisk and accelerate the process of bringing successful therapies to the patients who need them most.

Read Flipbook
over 2 years ago
A Humanized Preclinical in Vivo System to Predict the Immunotoxicity of Antibody Drug Candidates

James Keck, Ph.D., Senior Director, Innovation and Product Development, at JAX speaks about a humanized preclinical in vivo system to predict the the immunotoxicity of antibody drug candidates.

Watch Video
almost 3 years ago
CRS: FAQs

The JAX CRS assay has a highly flexible design applicable to a wide variety of human specific immune modulatory therapies. The assay can test both immunostimulatory and immunosuppressive therapies.

Learn More
over 2 years ago
Choosing the Appropriate Humanized FcRn Mouse Model to Test the Pharmacokinetics of Antibody Therapeutics

Read Flipbook
over 2 years ago
The Humanized FcRn Platform: An Essential Tool for Preclinical PK Assessment of Therapeutic Antibody Candidates

Greg Christianson, Study Director, In Vivo Services, The Jackson Laboratory speaks about the use of human FcRn transgenic mouse models to select antibody therapeutic candidates with optimum pharmacoki

Watch Video
over 3 years ago
JAX Guide: Assessing Antibody Pharmacokinetics Using the JAX FcRn Platform

Read Flipbook
over 2 years ago
Poster: Choosing the Appropriate Immune System- Humanized Mouse Model for Immuno-Modulatory Therapies

Read Flipbook
over 2 years ago
Human Immune System Engrafted Mice and Their Role in Human Antibody-Based Drug Development

Brian Soper, Ph.D., Senior Manager, Technical Information Services, The Jackson Laboratory speaks about human immune system engrafted mice and their role in human antibody-based drug development.

Watch Video
about 3 years ago
Mode of Action of TCell Bispecific Antibodies and their Combinations with Checkpoint Inhibitors

Johannes Sam, Roche Title: Studying the Mode of Action of TCell Bispecific Antibodies and their Combinations with Checkpoint Inhibitors and Immunomodulators in Humanized Mice

Watch Video
over 2 years ago
Testing the Efficacy of Immuno-Modulatory Antibodies in Humanized Mice

Aaron Rose, Ph.D., Senior Study Director, In Vivo Services, The Jackson Laboratory speaks about testing the efficacy of immunomodulatory antibodies in humanized mice.

Watch Video
about 4 years ago
The ABC’s of CAR T Cell Therapies

All that glitters… Cancer cells have found ingenious ways to evade the body’s immune system. These cells can shut off cytotoxic activity of anti-tumor...

Learn More

Return to Home

© The Jackson Laboratory